Agilent Technologies (A) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
8 Jul, 2026Executive summary
Q2 FY2025 revenue reached $1.67 billion, up 6% reported and 5.3% core year-over-year, exceeding expectations and guidance, with Ignite Transformation driving operational and financial performance.
Non-GAAP net income was $373 million (EPS $1.31, up 7%), while GAAP net income was $215 million (EPS $0.75, down 29%); net income declined due to lower margins and higher restructuring costs.
Growth was broad-based across all regions, with China up 10%, India in high teens, and all end markets except academia/government showing mid to high single-digit growth.
Ignite Transformation and restructuring initiatives contributed to productivity and efficiency, supporting EPS growth above revenue growth and targeting $75–80 million in annual cost reductions.
New segment structure implemented in Q1 2025, recasting historical segment data.
Financial highlights
Q2 revenue: $1.67 billion (+6% reported, +5.3% core); operating margin: 18.0% (down from 23.1%); gross margin: 51.9% (down from 54.4%).
Non-GAAP EPS: $1.31 (up 7%); GAAP EPS: $0.75 (down from $1.05); operating income: $300 million (down 17%).
Operating cash flow: $221 million in Q2; $652 million for the first half of 2025 (down from $818 million year-over-year).
Share repurchases: $165 million in Q2, $255 million in H1; dividends paid: $70 million in Q2, $141 million in H1.
Cash and cash equivalents at April 30, 2025: $1.49 billion.
Outlook and guidance
FY2025 revenue guidance raised to $6.73–$6.81 billion (3.4%–4.6% reported, 2.5%–3.5% core); non-GAAP EPS guidance: $5.54–$5.61.
Q3 FY2025 revenue guidance: $1.645–$1.675 billion (1.7%–3.6% core growth); non-GAAP EPS: $1.35–$1.37.
Tariff-related cost pressures expected in H2 2025, but substantial mitigation anticipated by year-end; full offset expected in 2026.
Ongoing investments in R&D, manufacturing, and applications portfolio to support future growth.
New $2B share repurchase program approved, effective August 2024.
Latest events from Agilent Technologies
- Enterprise transformation, margin growth, and specialty CDMO expansion drive 2026 outlook.A
Citi Annual Global Healthcare Conference 20259 Jul 2026 - Q4 revenue and EPS exceeded guidance, with FY26 projected for 4%-6% core and 5%-7% EPS growth.A
Q4 20259 Jul 2026 - Strong Q3 growth, margin recovery, and robust outlook driven by innovation and global demand.A
Wells Fargo 20th Annual Healthcare Conference 20258 Jul 2026 - Innovation, tech refresh, and AI initiatives fuel strong growth and margin expansion.A
Jefferies Global Healthcare Conference 20263 Jun 2026 - Q2 FY26 delivered double-digit revenue growth, margin expansion, and raised guidance.A
Q2 20261 Jun 2026 - Q1 FY26 revenue rose 7% to $1.8B, non-GAAP EPS up 4%, and FY26 guidance was raised.A
Q1 202614 Apr 2026 - siRNA manufacturing leadership drives growth in a $4B+ market with expanding capacity and innovation.A
Corporate presentation27 Mar 2026 - Strong growth, innovation, and disciplined strategy support positive outlook for the year.A
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Key votes include director elections, auditor ratification, and Board declassification.A
Proxy Filing6 Feb 2026